{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:20:33Z","timestamp":1791645633616,"version":"4.3.4"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"ABSTRACT<\/jats:title>\n \n \n \n Candida auris<\/jats:italic>\n is an evolving and concerning global threat. Of particular concern are bloodstream infections related to central venous catheters. We evaluated the activity of taurolidine, a broad-spectrum antimicrobial in catheter lock solutions, against 106\n C<\/jats:italic>\n .\n auris<\/jats:italic>\n isolates. Taurolidine was highly active with a MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n of 512\/512 mg\/L, over 20-fold lower than lock solution concentrations of \u226513,500 mg\/L. Our data demonstrate a theoretical basis for taurolidine-based lock solutions for prevention of\n C. auris<\/jats:italic>\n catheter-associated infections.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1128\/aac.00381-24","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T09:07:02Z","timestamp":1718183222000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["In vitro<\/i>\n activity of taurolidine against clinical\n Candida auris<\/i>\n isolates: relevance to catheter-related bloodstream infections"],"prefix":"10.1128","volume":"68","author":[{"given":"Bruce E.","family":"Reidenberg","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA"},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared L.","family":"Crandon","sequence":"additional","affiliation":[{"name":"CorMedix Inc., Berkeley Heights, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hurlburt","sequence":"additional","affiliation":[{"name":"CorMedix Inc., Berkeley Heights, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Tan","sequence":"additional","affiliation":[{"name":"CorMedix Inc., Berkeley Heights, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J. Ryan","family":"Arends","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4144-253X","authenticated-orcid":true,"given":"Antony","family":"Pfaffle","sequence":"additional","affiliation":[{"name":"CorMedix Inc., Berkeley Heights, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"CDC","year":"2019","unstructured":"CDC. 2019. Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services, CDC, Atlanta, GA."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00053-22"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz262"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00625-9"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mbo3.578"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2907.230540"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3469"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2021.10.037"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08477-5"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2022.87"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2672.1980.tb05210.x"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2021.10.022"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000178454"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.06.001"},{"key":"e_1_3_4_18_2","volume-title":"M27Ed4. Reference method for broth dilution antifungal susceptbility testing of yeasts","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. M27Ed4. Reference method for broth dilution antifungal susceptbility testing of yeasts. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_19_2","volume-title":"M27M44SEd3. Performance standards for antifungal susceptibility testing of yeasts","author":"CLSI","year":"2022","unstructured":"CLSI. 2022. M27M44SEd3. Performance standards for antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.18502\/cmm.8.1.9211"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2014.01.010"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00381-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00381-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:05:42Z","timestamp":1720515942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00381-24"}},"subtitle":[],"editor":[{"given":"Damian J.","family":"Krysan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,9]]}},"alternative-id":["10.1128\/aac.00381-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00381-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2024-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00381-24"}}